Skip to content
About
Pipeline
MB-105
News & Publications
Menu
About
Pipeline
MB-105
News & Publications
Contact
Contact
About
Pipeline
MB-105
News & Publications
Menu
About
Pipeline
MB-105
News & Publications
March Biosciences Awarded $13.4 Million by CPRIT to Advance Its CD5 CAR-T Therapy for T-cell Lymphoma in Phase 2 Trials
November 17, 2023
7:00 am
Prev
Previous
Cancer Focus Fund invests $4.8M into Houston-based March Biosciences
Next
Cell therapy developed by Baylor scientists shows promise as woman remains cancer-free after 5 years
Next
Scroll Up
